In 1999, Freytag et al. targeted the CD/HSV-tk fusion gene to tumors with the virus by constructing Ad5-CD/TKrep and demonstrated the destruction of tumor cells in vitro while exhibiting minimal cytotoxicity to normal cells. Here, TKT is linked to neoplasm.